@article{Dellamora_Peak_2019, title={TRANSLATIONAL RESEARCH AND THE CONTRIBUTION OF CLINICAL PHARMACISTS TO HEALTH SERVICES: Pesquisa translacional e a contribuição de farmaceuticos clínicos nos serviços de saúde}, volume={6}, url={https://rbfhss.org.br/sbrafh/article/view/235}, abstractNote={<p>Translating the results of medical research into clinical practice in healthcare services is a<br>considerable challenge faced by health systems1,2. To fill this gap, translational research (TR) has been<br>emphasized as a way to transform the results of basic and applied research into real alternatives for the<br>prevention, diagnosis and treatment of disease2,3,4.<br>When considering the scope of TR, we tend to think of the so-called ‘bench to bedside’, which<br>aims, for example, to build a bridge between basic research and the introduction of a new pharmaceutical<br>formulation to the market4<br>. Nevertheless, there are other phases of TR such as using the best available<br>evidence in clinical practice, as well as assessing the implementation of new care guidelines in health<br>outcomes4,5. These phases have the utmost importance in the field of pharmacy, especially with regard to<br>pharmaceutical services.<br>In general, new drugs afford only incremental improvements, and patients may actually gain<br>greater clinical benefit if established therapeutic alternatives are used properly4,6. In Brazil, despite advances<br>in the elaboration of clinical protocols and therapeutic guidelines for high complexity care, serious problems<br>remain owing to pressure in the process of incorporating new health technologies within the scope of the<br>services7<br>. Intensive processes of adoption and marketing can be associated with such technologies, which<br>do not always have a health impact but are often in demand from the public and profitable for the industry,<br>entailing methodological challenges to guarantee the safety of patients4<br>.<br>The transfer of knowledge from basic research to application is stimulating and depends on the<br>close integration of researchers and health, government and academic institutions, which is a challenge<br>for most countries8<br>. Several postgraduate programs in Brazil and around the world have sought to bring<br>the researcher closer to the field of practice9<br>. Nevertheless, Bornstein and Licinio8<br> have highlighted how<br>both the distance between research and clinical practice and their financing by different entities reduce the<br>effectiveness of translation initiatives. In Brazil, this is compounded by the challenge of running a public<br>health system for approximately 200 million inhabitants across 5565 cities with 491,603 hospital beds.<br>In the United Kingdom, Germany, Australia, Singapore and the United States, the best<br>universities, health services, and medical research institutes have worked together to achieve progress in the<br>way that health care is delivered to the community8<br>. Recently, the American College of Clinical Pharmacy<br>underscored the importance of developing capabilities for pharmacists to be able to perform research<br>that meets the growing demands of society10. TR that incorporates methods in clinical pharmacology can<br>generate new skills that guide the decisions in selecting and following-up drug therapy11. However, there is<br>a need to train pharmacists and to expand the number of graduate programs that encompass this area, as<br>well as increasing the number of qualified mentors11.<br>In the United Kingdom, the National Institute for Health Research (NIHR) financed a fiveyear program called Adverse Drug Reactions in Children (ADRIC), resulting in improvements in the<br>management and understanding of adverse drug reactions in both children and adults within the health<br>syste12. Researchers from universities and health institutions in London and Liverpool have developed new<br>tools for assessing the causality and avoidability of adverse drug reactions, in addition to developing better<br>strategies for communicating with the families of patients when an adverse drug reaction is suspected. The<br>role of clinical and research pharmacists in study design, study implementation and data interpretation is<br>essential in such research programmes.<br>On the one hand, the academic output in the first phase of TR has shown exponential growth5<br>.<br>On the other hand, the output of other phases has been sometimes slow, although it is apparent as protocols,<br>guidelines and handbooks of great importance for the health system8<br>. In addition to the required efforts in<br>inter-institutional cooperation and financing of these studies in Brazil, scientific communication journals<br>in this field also are needed. In this respect, the Brazilian Society of Hospital Pharmacy and Health Services<br>(RBFHSS), hopes to contribute directly to the disclosure of knowledge derived from TR in health services<br>in Brazil and Latin America.</p>}, number={4}, journal={Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde}, author={Dellamora, Elisangela da Costa Lima- and Peak, Matthew}, year={2019}, month={Jun.} }